Company intelligence / Profile preview

Nanjing Carephar Pharmaceutical

Ownership: Private
Development stage: Other

Overview

Nanjing Carephar Pharmaceutical is a clinical-stage biopharmaceutical company based in Nanjing, China, specializing in the discovery and development of innovative small molecule therapeutics. The company primarily focuses on metabolic diseases, particularly hyperuricemia and gout, as well as oncology and autoimmune disorders. Its lead candidate, CP-011, is a potent URAT1 inhibitor designed to provide superior efficacy and safety for patients with chronic gout. Carephar integrates R&D, clinical development, and manufacturing capabilities to advance its pipeline of high-potential drug candidates toward commercialization.

Therapeutic areas: RheumatologyMetabolic Disorders
Modalities: Small molecule
Industry: Biotech

Drug pipeline

6 assets

SIPI-7623

5 more assets in the full pipeline.

Beyond the preview

Go deeper on Nanjing Carephar Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nanjing Carephar Pharmaceutical.